The Drug Discovery for the Nervous System (DDNS) reviews applications proposing preclinical work aimed at discovering new pharmacotherapeutic and immunotherapeutic agents for treating or preventing disorders of the nervous system, including drug abuse, that will eventually lead to clinical trials and approval by FDA.
The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Medicinal chemistry focusing on the discovery and refinement of molecules as a prelude to clinical use combined with biological evaluation to determine their potential as therapeutics.
- Development of protein-based therapies, including drug specific metabolizing enzymes, drug-protein conjugate vaccines, drug-specific antibodies, and biologics.
- Isolation, characterization and refinement of promising natural products to identify potential uses for disorders of the nervous system.
- Development of screening assays and preclinical animal models or their use to evaluate candidate therapeutic compounds for future drug development.
- Development of delivery systems that target compounds to the brain, including gene vectors, stem cells, protein and peptide delivery systems, and nanoparticle delivery systems.
- Pharmacokinetic approaches in drug discovery, including the determination of blood brain barrier permeability of candidate compounds, pro drugs, and pharmacokinetic modifications. Repurposing of approved drugs, including proof of principle studies for target validation.
Shared Interests and Overlaps
Cellular and Molecular Biology of Neurodegeneration (CMND): There is shared interest in neurodegeneration. Applications that contain mechanistic studies necessary to progress drug discovery are appropriate for DDNS. Applications with a major focus on mechanisms of neurodegeneration are better suited for CMND.
Neural Oxidative Metabolism and Death (NOMD): There is shared interest in cell death. Applications that contain mechanistic studies necessary to progress drug discovery are appropriate for DDNS. Applications with a major focus on mechanisms of cell death are better suited for NOMD.
Neurobiology of Motivated Behavior (NMB): There is shared interest in behavioral studies. Applications that contain behavioral studies necessary to progress drug discovery are appropriate for DDNS. Applications with a major focus on motivated behavior are better suited for NMB.
Gene and Drug Delivery Systems Study Section [GDD]: There is shared interest in development and delivery of drugs, vaccines, genes, small molecules and biomaterials. Applications involving products that alter gene function or expression may be reviewed in GDD whereas applications focused on development and delivery to the nervous system may be reviewed in DDNS.
Neurobiology of Pain and Itch (NPI); There is shared interest in discovery and development of innovative non-pharmaceutical approaches to pain therapy. Applications implementing medicinal chemistry for preclinical research, drug screening and preclinical animal models, natural product development, and pharmacokinetic evaluation would likely be reviewed by DDNS
There are shared interests in neuropharmacology and neurochemistry with Molecular Cellular Neruopharmacology (MCNP). Applications that emphasize the synthesis of such drugs are reviewed in DDNS. Applications that emphasize the molecular and cellular action of neuroactive drugs are reviewed in MCNP.